Moderna (MRNA)’s Melanoma Vaccine Win: Big Opportunity, Bigger Expectations
Moderna's personalized mRNA cancer vaccine, Intismeran, has shown positive results in a late-stage trial for treating melanoma. This success offers the company a significant opportunity to diversify its revenue beyond COVID-19 products.
Why it matters
Represents a potential breakthrough in oncology treatment and a major pivot for a significant biotech firm.
Moderna (MRNA)’s Melanoma Vaccine Win: Big Opportunity, Bigger Expectations Vardah Gill Wed, August 19, 2026 at 5:58 PM EDT 5 min read MRNA +176.97% Trade Moderna on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in